# Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

> **NCT00748163** · PHASE2 · WITHDRAWN · sponsor: **Masonic Cancer Center, University of Minnesota**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** paclitaxel albumin-stabilized nanoparticle formulation
- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00748163
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-08
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study has been abandoned for lack of available funding.
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00748163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00748163, "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00748163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*